This study is to assess the safety and tolerability aspects of oral MGB-BP-3, a treatment for
Clostridium difficile infections.
Phase:
Phase 1
Details
Lead Sponsor:
MGB Biopharma Limited
Collaborators:
Analytical Services International Limited Cambridge Regulatory Services Hammersmith Medicines Research Innovate UK Phases Clinical Research Limited Synlab Services Viapath